Ask AI
Biomarker Testing in HRpos HER2neg ABC

CE / CME

Unmet Needs, Mechanisms of Resistance, and Biomarker Testing in HR+/HER2- Advanced Breast Cancer Progressing on First-line CDK4/6 Inhibitor Plus Endocrine Therapy

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: May 30, 2025

Expiration: December 25, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case



  • A 67-yr-old woman was diagnosed with de novo metastatic breast cancer to bones 3 yr ago

  • At that time, bone and breast biopsy revealed adenocarcinoma
    ER-positive, PgR-positive, HER2-negative disease

  • Tumor genomics did not reveal actionable mutations

  • Treatment with ribociclib plus letrozole was initiated

  • Recent scans show disease progression in her bones

  • At this time, ctDNA analysis of the patient’s blood sample is performed

Which of the following is the most likely molecular alteration(s) that will be seen on ctDNA analysis?